BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Anthill Technologies Announces Agreement With Zafgen


8/26/2008 9:42:34 AM

WOBURN, Mass., Aug. 25 /PRNewswire/ -- Anthill Technologies, Inc. today announced that it has entered into an agreement with Zafgen, Inc. to apply its high-speed chemistry technologies and capabilities to Zafgen's obesity program. Zafgen, Inc. is a Boston-based biopharmaceutical company which develops obesity therapy based on the vascular targeting of adipose tissue.

Under the agreement, Anthill will use its ACOS(TM) high-speed synthesis and on-demand purification capabilities to assist Zafgen in the development of lead compounds for its obesity therapy programs. "We are very pleased to have the opportunity to assist Zafgen in its efforts to find novel and effective therapies to combat obesity," said Dr. Joseph C. Hogan Jr., CEO of Anthill Technologies. "We fully expect that our high-speed chemistry expertise and unique capabilities will help Zafgen to accelerate its obesity therapy discovery program."

Anthill Technologies, Inc. is pioneering the development and commercialization of high-speed chemistry technologies and systems for application across the chemical industry. Founded in 2005, the Company has developed and applied the first in a continuing series of high-speed chemistry systems, known as Applied Chemistry Operating Systems, or ACOS(TM), which are designed to dramatically reduce the time, cost and risks associated with discovering and developing chemical compositions, processes and products for both industrial and pharmaceutical applications. Additional information about Anthill Technologies is available on the Company's website at http://www.anthilltechnologies.com.

CONTACT: Anthill Technologies, Inc., +1-781-937-5558, fax, +1-781-973-4223

Web site: http://www.anthilltechnologies.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES